Technical Analysis for INO - Inovio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 5.09 0.20% 0.01
INO closed up 0.2 percent on Friday, January 18, 2019, on 69 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical INO trend table...

Date Alert Name Type % Chg
Jan 18 New Uptrend Bullish 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 17 MACD Bullish Centerline Cross Bullish 0.20%
Jan 17 Stochastic Reached Overbought Strength 0.20%
Jan 17 Wide Bands Range Expansion 0.20%
Jan 17 Overbought Stochastic Strength 0.20%
Jan 17 Up 3 Days in a Row Strength 0.20%

Older signals for INO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company's DNA-based SynCon technology enables the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. Inovio Pharmaceuticals, Inc. has collaboration and license agreements with VGX International, Merck, and ChronTech. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.
Is INO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.3
52 Week Low 3.64
Average Volume 860,779
200-Day Moving Average 4.7653
50-Day Moving Average 4.8502
20-Day Moving Average 4.4765
10-Day Moving Average 4.834
Average True Range 0.2522
ADX 25.21
+DI 27.384
-DI 14.4059
Chandelier Exit (Long, 3 ATRs ) 4.3434
Chandelier Exit (Short, 3 ATRs ) 4.5066
Upper Bollinger Band 5.2848
Lower Bollinger Band 3.6682
Percent B (%b) 0.88
BandWidth 36.113035
MACD Line 0.0556
MACD Signal Line -0.0404
MACD Histogram 0.096
Fundamentals Value
Market Cap 459.25 Million
Num Shares 90.2 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -4.76
Price-to-Sales 9.78
Price-to-Book 3.53
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.35
Resistance 3 (R3) 5.33 5.21 5.31
Resistance 2 (R2) 5.21 5.15 5.23 5.29
Resistance 1 (R1) 5.15 5.11 5.18 5.18 5.28
Pivot Point 5.04 5.04 5.05 5.05 5.04
Support 1 (S1) 4.98 4.97 5.01 5.00 4.90
Support 2 (S2) 4.86 4.93 4.88 4.89
Support 3 (S3) 4.80 4.86 4.87
Support 4 (S4) 4.83